Skip to content

ANEBULO PHARMACEUTICALS, INC.

ANEB

CIK 0001815974

← back to feed
Revenue (TTM)
—
Q2 Feb 2026
Net Income (TTM)
−$8.3M
−3.5% YoY Q2 Feb 2026
EPS Diluted (TTM)
−$0.23
+21.9% YoY Q2 Feb 2026
Gross Margin
—
Q2 Feb 2026
Operating Margin
—
Q2 Feb 2026
Net Margin
—
Q2 Feb 2026
Free Cash Flow (TTM)
—
Q2 Feb 2026
Cash
$9.04M
Q2 Feb 2026
Total Debt
—
Q2 Feb 2026
Shares Outstanding
40.78M sh
Q2 Feb 2026

Revenue & Net Income

EPS (Diluted)

Cash Flow

Revenue Growth (YoY)

No data available for this metric.

Balance Sheet

Cash vs Debt

Recent filings